Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9053090 | 1.00 | KMT2A (0.46) | KMT2AHSD11B1CYP2D6ALDH1A1HPGD | |
| SCHEMBL9053086 | 1.00 | KMT2A (0.46) | KMT2AHSD11B1CYP2D6ALDH1A1HPGD | |
| SCHEMBL3197183 | 0.94 | KMT2A (0.44) | KMT2AHSD11B1CYP2D6ALDH1A1HPGD | |
| SCHEMBL3197180 | 0.94 | KMT2A (0.44) | KMT2AHSD11B1CYP2D6ALDH1A1HPGD | |
| SCHEMBL15099775 | 0.84 | KMT2A (0.47) | KMT2AHSD11B1CYP2D6ALDH1A1HPGD | |
| SCHEMBL20183376 | 0.84 | KMT2A (0.47) | KMT2AHSD11B1CYP2D6ALDH1A1HPGD | |
| SCHEMBL20183374 | 0.84 | KMT2A (0.47) | KMT2AHSD11B1CYP2D6ALDH1A1HPGD | |
| SCHEMBL20183457 | 0.84 | KMT2A (0.47) | KMT2AHSD11B1CYP2D6ALDH1A1HPGD | |
| SCHEMBL3194067 | 0.84 | KMT2A (0.47) | KMT2AHSD11B1CYP2D6ALDH1A1HPGD | |
| SCHEMBL20183458 | 0.84 | KMT2A (0.47) | KMT2AHSD11B1CYP2D6ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2437601-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20120071459-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2012-03-22 | — | — | US | disclosed |
| US-20120071459-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2012-03-22 | — | — | US | disclosed |
| US-20120071459-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2012-03-22 | — | — | US | disclosed |
| WO-2010141545-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141545-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2010-12-09 | — | — | WO | disclosed |
| EP-0341493-B1 | Optically active pyridonecarboxylic acid derivatives | DAIICHI SEIYAKU CO (JP) | 1999-07-14 | — | — | EP | disclosed |
| EP-0871628-A1 | QUINOLIZINONE TYPE COMPOUNDS | Abbott Laboratories (US) | 1998-10-21 | — | — | EP | disclosed |
| EP-0529688-B1 | Azaspiro(n,m)alkanes and diazaspiro(n,m)-alkanes | DAIICHI SEIYAKU CO (JP) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5508428-A | Spiro compound | DAIICHI PHAMACEUTICAL CO., LTD. (JP) | 1996-04-16 | — | — | US | disclosed |
| US-5286723-A | Spiro compound | DAIICHI SEIYAKU CO., LTD. | 1994-02-15 | — | — | US | disclosed |
| EP-0357047-B1 | Spiro compounds | DAIICHI SEIYAKU CO (JP) | 1993-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071459-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | MCHR1, MCHR2, MC1R | KMT2A 2648/4885HSD11B1 788/4885CYP2D6 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.